Global Women's Health Market Report Segmented by Product Type (ACTONEL, FORTEO, Mirena, NuvaRing, Premarin), Application (Female Infertility, Menopause, Endometriosis), Age Group (Adolescents, Adult Women, Elderly Women), End-user & Forecast

The global women -s health market is expected to grow at a rate of 5% during the forecast period. Rising prevalence of chronic diseases such as breast cancer and osteoporosis, growing demand for contraception and increased initiatives by the government and NGO are some of the key factors driving the market growth. However, side effects associated with the use of contraceptive pills, hormonal therapies and the complex regulatory approval process remain some key barriers for the growth of the women"https://meditechinsights.com/global-womens-health-market/request-sample/">To learn more about the research report, download a sample report.

One-half of the worlds population is women, and they account for ~80% of consumer purchasing decisions in the healthcare industry. Womens health refers to the branch of medicine that focuses on the biological, psychological, and social factors affecting the health and well-being of women throughout their lives. The central focus is on reproductive care, which includes menstruation, contraception, pregnancy, childbirth, and menopause. Additionally, it also addresses the management of other reproductive system disorders such as polycystic ovary syndrome (PCOS), endometriosis, and gynecological cancers like cervical and ovarian cancer.

Beyond reproductive health, women are also at higher risk for several non-reproductive conditions, such as osteoporosis, which is more prevalent in women due to hormonal changes that affect bone density, especially after menopause. Breast cancer remains one of the most prevalent and serious threats to women's health globally. Understanding these un womens health concerns is vital to improve early diagnosis, access to treatment or care, and health outcomes for women at every life stage.

To learn more about this report, download the PDF brochure

Growing Burden of Chronic Illness in Women

The increasing incidence of chronic conditions among women, such as cancer and osteoporosis, is the major growth driver of the market. These conditions often require gender-specific measures for prevention, diagnosis, and treatment. The risk factors associated with the occurrence of such diseases are family history, increasing age, early onset of periods or menopause and obesity, among others. For example, in March 2021, the World Health Organization (WHO) initiated the Global Breast Cancer Initiative (GBCI) intending to decrease breast cancer mortality rates by 2.5% annually until 2040, thereby potentially saving 2.5 million lives. With the growing focus on prevention and awareness programs, more women are being diagnosed with critical health conditions, driving the demand for products and services designed for womens health care. For instance,

• In Februa 2024, Hologic, Inc. launched the first digital cytology system using advanced volumetric imaging for the detection of precancerous and cervical cancer cells in the US

Rising Demand for Contraceptives to Drive the Womens Health Market

The growing demand for contraceptives is a significant driver for the women's health market. As awareness about family planning and reproductive health increases, more women are opting for various contraceptive methods to control their fertility and prevent unintended pregnancies. This demand is fueled by educational initiatives, improved access to healthcare services, and a shift towards proactive health management. Contraceptives, including oral pills, intrauterine devices (IUDs), implants, and injectables, offer women the ability to plan their families and careers, contributing to better overall health and economic stability. Additionally, the rise of new and improved contraceptive technologies, such as long-acting reversible contractives (LARCs), provides more options that cater to different preferences and needs. Government and non-governmental organizations' efforts to promote contraceptive use and improve accessibility, particularly in developing regions, further bolster this market

To learn more about this report, download the PDF brochure

Technological innovations in womens healthcare

Advancements in diagnostic technologies have enabled early and precise detection of diseases such as breast cancer, osteoporosis, and reproductive disorders. Digital health tools such as telehealth platforms, mobile apps and wearable devices are now assisting women to take care of their health in a more personalized way. These tools enable continuous health tracking, symptom monitoring, medication reminders, and virtual consultations, increasing accessibility to care, especially in remote and underserved areas. Further, the integration of AI & M/L in the diagnosis and treatment of various diseases has created new opportunities and demands in the market.

• In January 2025, GE HealthCare introduced its enhanced Voluson Expert Series (models22,20,18), which received FDAclearance, featuring AI-powered imaging, advanced automation (like SonoLyst and Graphicflow), and ergonomic design to boost early detection and exam efficiency in womens health ultrasound
• In March 2024, Sirio Pharma unveiled a personalized 25formulation womens health platform at Vitafoods Europe, featuring gummies and softgels tailored to life stages frough menopause, addressing PMS, fertility, prenatal/postnatal care, UTI protection, gut health, weight management, sleep, and menopausal wellbeing
• In February 2023, Samsung HERA W10 Elite ultrasound system was launched, which was designed for Obstetrics and Gynecology, offering advanced imaging capabilities and AI-powered tools

Emerging Opportunities in Womens Health Market

A new era of innovation is unfolding in womens health, which is driven by groundbreaking scientific and technological advancements, thereby offering transformative opportunities to address long-standing gaps in diagnosis, treatment, and care. Conditions such as preeclampsia, endometriosis, and hormone-related disordersare now being explored with greater precision and purpose. Emerging fields like genomics, tissue engineering, artificial intelligence, and cell and gene therapy are unlocking novel ways to develop targeted solutions for female-specific health challenges. For example, rhers are studying transcriptomics (the study of RNA molecules in a cell) for treating elusive conditions such as preeclampsia or preterm birth. On the other hand, tissue engineering is being used to create uterine organoids to push the knowledge frontier on endometriosis.Genomicsis another research area that can help researchers in realizing the potential of personalized medicine. There has been extraordinary growth in terms of technology from predictive AI solutions to modelling unique DNA profiles, which uses machine learning algorithms to analyse user data to provide unique, actionable insights and treatment plans related to symptom progression. A favourable environment for research activities is expected to further drive growth opportunities in this market.

Womens health is not a niche market; it includes much more than just maternal or reproductive care. Indeed, womens healthcare presents enormous opportunities for value creation and for improving the lives and livelihoods of women, with positive effects that redound across "

-Executive Vice President, Global Operations and Supply Chain, Womens Health Company, United States

Product Type Segment Analysis

The womens health market comprises two products like: ACTONEL, YAZ (Yasmin, Yasminelle), FORTEO, Mirena, NuvaRing, ORTHO TRI-CY LO, Premarin, Prolia, Reclast/Aclasta, XGEVA, Zometa, Others. The Prolia segment is likely to lead the market and is projected to grow at the fastest rate over the forecast period. Prolia, whose generic name is denosumab, is a medication used in women's health for treating and preventing osteoporosis in postmenopausal women. It is widely used for the treatment of osteoporosis in postmenopausal women at high risk of fractures. Prolia has established a significant market presence due to its effectiveness in reducing the incidence of fractures and its biannual dosing regimen, which improves patient compliance compared to other osteoporosis treatments.

The Minastrine segment is expected to grow at a lucrative CAGR over the forecast period due to its user-friendly dosing schedule and minimal side effects. It combines low-dose estrogen with progestin and iron, which helps manage both birth control and iron deficiency, appealing to women seeking dual benefits. The 24-day active pill regimen, with fewer placebo days, is preferred for its convenience and reduced occurrence of withdrawal bleeding. Additionally, increasing awareness of hormonal contraception's benefits and growing demand for effective, well-tolerated contraceptive options contribute to Minastrin 24 Fe's expanding market presence.

Application Type Segment Analysis

The womens health market can be analyzed based on application types, such as Female Infertility, Contraceptives, Postmenopausal osteoporosis, Endometriosis, Menopause, and Others. The contraceptives represent the largest segment. The widespread use of contraceptives for both pregnancy prevention and management of metrual-related issues drives this large market segment. Contraceptives benefit from extensive awareness, strong demand, and ongoing innovation, which maintains their dominant position. The fastest-growing segment is postmenopausal osteoporosis. The incidence of osteoporosis among postmenopausal women is increasing continuously. This growth is driven by an aging demographic, rising awareness of bone health, and advancements in treatment options. Additionally, increased focus on preventive care and proactive management of bone density is accelerating growth in this area. The combination of a growing patient population and a heightened emphasis on osteoporosis prevention and treatment supports its position as the fastest-growing segment in the womens health market.

Growth Strategies Adopted by Players to Establish Their Foothold in the Market

Players operating in this market are adopting different growth strategies such as new product launches and approvals to garner market sha. For instance,

• In May 2024, The FDA approvedSandozs Jubbonti and Wyost as interchangeable biosimilars to Prolia and Xgeva, respectively, for treating certain types of osteoporosis and preventing bone events in cancer. These approvals enhance treatment accessibility and demonstrate the biosimilars' similar safety and efficacy to their reference products
• In January 2024,Bayer HealthcaresMirena, a 52mg Levonorgestrel IUD, received FDA approval for contraceptive to extend of this device, for contraception only, to eight years. The approval is particularly beneficial for younger perimenopausal women needing contraception, while the license for treating heavy menstrual bleeding and endometrial protection remains unchanged
• In November 2023,Teva Pharmaceuticalsreceived USFDA of a generic version of Forteo (teriparatide injection) for osteoporosis treatment. This approval enhances patient accesoporosis treatment and supports Tevas goal of maintaining its position as a leading generic pharmaceutical company

The womens health market is expected to gain further momentum in the coming years due to impending patent cliff, rising R&D investments, new product launches, and aggressive organic and inorganic growth strategies followed by the players.

Competitive Landscape Analysis

The global womens health market is marked by the presence of established and emerging market players such as Bayer AG, Amgen, AbbVie, Pfizer, Ferring Pharmaceutical, Novartis, Organon & Co., Apothecus Pharmaceutical Corp, Theramex, and Blairex Laboratories. Some of the key strategies adopted by market players include new product development, strategic partnerships and collaborations, and geographic expansion.

Report Scope

Report Metric	Details
Base Year Considered	2024
Historical Data	2023 - 2024
Forecast Period	2025 2030
Growth Rate	5%
Market Drivers	Rising prevalence of chronic conditions among women Growing demand for contraceptives Rising awareness and focus on preventive care for womens health issues Increasing government and NGO support for maternal health Technological advancement in diagnostics and telemedicine for women's health
Attractive Opportunities	Growth in femtech and personalized mobile health solutions Increased focus on women's mental health Rising demand for non-invasive diagnostic and therapeutic devices Untapped rural and emerging markets for womens wellness products
Segment Scope	Product Type, Application, Age Group and End-user
Regional Scope	North America (US & Canada) Europe (UK, Germany, France, Italy, Spain, Rest of Europe) Asia Pacific (China, India, Japan, Rest of Asia Pacific) Latin America Middle East & Africa
Key Companies Mapped	Bayer AG, Amgen, AbbVie, Pfizer, Ferring Pharmaceutical, Novartis, Organon & Co., Apothecus Pharmaceutical Corp, Theramex, and Blairex Laboratories, among others
Report Highlights	Market Size & Forecast, Growth Drivers & Restraints, Trends, Competitive Analysis

Global Womens Health Market Segmentation

This report by Medi-Tech Insights provides thesize of the global womens health market at theregional- and country-level from 2023 to 2030. The report further segments the market based on product type, application, age group and end-user.

Market Size & Forecast (2023-2030), By Product Type, USD Million

• ACTONEL
• YAZ, Yasmin, Yasminelle
• FORTEO
• Mirena
• NuvaRing
• ORTHO TRI-CY LO
• Premarin
• Prolia
• Reclast/Aclasta
• XGEVA
• Zometa
• Others

Market Size & Forecast (2023-2030), By Application, USD Million

• Female Infertility
• Contraceptives
• Postmenopausal Osteoporosis
• Menopause
• Endometriosis
• Others

Market Size &recast (2023-2030), By Age Group, USD Million

• Adolescents
• Adult Women
• Elderly Women

Market Size & Forecast (2023-2030), By End-user, USD Million

• Hospitals
• Clinics
• Homecare settings
• Others

Market Size & Forecast (2023-2030), By Region, USD Million

• North America
  • US
  • Canada
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Rest of Europe
• Asia Pacific
  • China
  • India
  • Japan
  • Rest of Asia Pacific
• Latin America
• Middle East & Africa

Key Strategic Questions Addressed

• What is the market size & forecast of the womens health market?
• What are historical, present, and forecasted market shares and growth rates of various segments and sub-segments of the womens health market?
• What are key trends defining the market?
• What are the major factors impacting the market?
• What are the opportunities prevailing in the market?
• Which region has the highest share in the global market? Which region is expected to witness the highest growth rate in the next 5 years?
• Who are the major players operating in the market?
• What are the key strategies adopted by players?